At the heart of the Dutch court case on Humira is the question of whether there ought to be limits to what a company can ...

A report from the inspector general of HHS examines the latest trends since several biosimilar versions of Humira were ...

House Republicans are considering nixing a Medicaid drug-pricing plan floated by President Trump and fiercely opposed by ...

Biosimilars are gaining traction as competitors aim to capture market share from branded biologics such as Humira and ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

AbbVie's rheumatoid arthritis blockbuster Humira is set for $15 billion in revenues this year, but the first biosimilars could be on the US market as early as next year. The US company had pinned ...

Humira (adalimumab) is a prescription drug that’s used to treat certain conditions, such as rheumatoid arthritis. Humira can cause side effects that range from mild to serious. Examples include ...

European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s market share later this year between Amgen, Boehringer Ingelheim ...

Humira has been the world’s best selling medicine since it arrived on the market in 2002. Now, it is finally getting competition with the release of Amgen’s biosimilar drug, Amjevita.

AbbVie Inc. beat revenue & EPS estimates, raised guidance due to Skyrizi & Rinvoq growth. Immunology shines; future expansions expected. Click to read my ABBV update.

Drugmaker AbbVie plans to invest more than $10 billion in domestic manufacturing and other capabilities over the next decade, ...

AbbVie stock outperformed S&P 500 with a +16% to 9.41% return since November 2023, despite Humira revenue declining 38% to $8.99 billion. Immunology drugs Skyrizi and Rinvoq grew over 50% year ...